BMO Capital Markets started coverage on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research report released on Thursday, BenzingaRatingsTable reports. The firm issued an outperform rating and a $45.00 price objective on the biopharmaceutical company’s stock.

AGIO has been the subject of several other research reports. BidaskClub lowered shares of Agios Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, September 6th. Goldman Sachs Group restated a neutral rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, May 23rd. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a sell rating to a hold rating and set a $46.00 target price for the company in a report on Wednesday, August 14th. Cowen restated a buy rating on shares of Agios Pharmaceuticals in a report on Friday, May 31st. Finally, Royal Bank of Canada set a $89.00 target price on shares of Agios Pharmaceuticals and gave the stock a buy rating in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $68.57.

AGIO stock traded down $0.41 during trading on Thursday, hitting $37.74. 927,387 shares of the company’s stock traded hands, compared to its average volume of 529,177. Agios Pharmaceuticals has a 52 week low of $33.17 and a 52 week high of $79.17. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.91 and a current ratio of 5.96. The business has a fifty day simple moving average of $40.88 and a 200 day simple moving average of $51.45. The stock has a market capitalization of $2.24 billion, a price-to-earnings ratio of -6.22 and a beta of 2.22.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.70) by ($0.17). The firm had revenue of $26.22 million during the quarter, compared to the consensus estimate of $27.05 million. Agios Pharmaceuticals had a negative return on equity of 59.89% and a negative net margin of 383.05%. Agios Pharmaceuticals’s revenue was down 35.1% compared to the same quarter last year. During the same quarter last year, the business posted ($1.19) EPS. Research analysts forecast that Agios Pharmaceuticals will post -7.12 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its holdings in Agios Pharmaceuticals by 27.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 182,150 shares of the biopharmaceutical company’s stock valued at $8,399,000 after buying an additional 39,255 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Agios Pharmaceuticals by 14.6% during the 4th quarter. Geode Capital Management LLC now owns 546,568 shares of the biopharmaceutical company’s stock valued at $25,202,000 after buying an additional 69,603 shares in the last quarter. Comerica Bank bought a new stake in Agios Pharmaceuticals during the 1st quarter valued at about $871,000. State Board of Administration of Florida Retirement System lifted its holdings in Agios Pharmaceuticals by 1.2% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 74,257 shares of the biopharmaceutical company’s stock valued at $5,008,000 after buying an additional 860 shares in the last quarter. Finally, TD Asset Management Inc. lifted its holdings in Agios Pharmaceuticals by 26.6% during the 1st quarter. TD Asset Management Inc. now owns 52,668 shares of the biopharmaceutical company’s stock valued at $3,552,000 after buying an additional 11,068 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Recommended Story: How is a price target determined?

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.